HOUSTON, March 12, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, today announced the
pricing of an underwritten public offering of 28,572,000 shares of
its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker
from the offering, before deducting the underwriting discounts and
commissions and other estimated offering expenses, are expected to
be approximately $50.0 million. In addition, Marker has
granted the underwriters a 30-day option to purchase up to an
additional 4,285,800 shares of its common stock. All of the shares
to be sold in the offering are to be sold by Marker. The offering
is expected to close on or about March 16,
2021, subject to customary closing conditions.
Piper Sandler & Co. is acting
as the sole active book-running manager for the offering. Cantor
Fitzgerald & Co. is also acting as a book-running manager for
the offering. Oppenheimer & Co. Inc. is acting as the lead
manager and Roth Capital Partners is acting as the co-manager for
the offering.
The offering is being made pursuant to a shelf registration
statement, including a base prospectus, filed by Marker that was
declared effective by the Securities and Exchange Commission
("SEC") on June 25, 2019. The
offering is being made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. An electronic copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering has
been filed with the SEC and is available on the SEC's website at
www.sec.gov. Copies of the final prospectus supplement, when
available, and the accompanying prospectus relating to the offering
may be obtained by contacting Piper
Sandler & Co., Attention: Prospectus Department,
800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, by telephone at (800) 747-3924 or by email
at prospectus@psc.com; or Cantor Fitzgerald & Co.,
Attention: Capital Markets Department, 499 Park Avenue,
New York, NY 10022, or
email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding market risks and
the satisfaction of customary closing conditions for an
offering of securities. Forward-looking statements are by their
nature subject to risks, uncertainties and other factors that could
cause actual results to differ materially from those stated in such
statements. Such risks, uncertainties and factors include, but are
not limited to the risks set forth in the Company's most recent
Annual Report on Form 10-K and other SEC filings that are available
through EDGAR at www.sec.gov. Such risks and uncertainties may be
amplified by the COVID-19 pandemic and its impact on our business
and the global economy. The Company assumes no obligation to update
our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-inc-announces-pricing-of-public-offering-of-common-stock-301246161.html
SOURCE Marker Therapeutics, Inc.